Storage-dependent changes in blood and components as affecting a patient with acute haemorrhage are described. With currently used preservatives and additives blood qualifies as ''fresh'' for two weeks after collection. Modified red cell concentrates are the optimal form of initial haemotherapy, with the possible exception of massive blood transfusion. A vailability of platelet concentrates and other haemostatic blood components as routinely issued by a modern blood bank should meet almost all requirements for an acutely bleeding patient.
practice based mainly on our ability to store and issue safe blood.
The sheer volume and diversity of operation of a modern blood bank is still due to our ability to store blood, and in addition to isolate its various components. That 300,000 blood donations were so handled in the State of New South Wales during the past year is just one indication of the extent and efficacy of the present system. It would be unthinkable, with current blood transfusion facilities, to allow any patient to die because of a lack of support with safe blood. In Australia, the Government has charged the Australian Red Cross Society with the responsibility of provision of blood to hospitals on the basis of a voluntary system of blood donations. The blood banks supervise donor selection, donor care, and regulate the technically complex procedures in the production of blood components. It is not practicable any longer to rely on direct transfusion, or "emergency" call-up of donors to meet the routine demands of hospital practice. Blood banks have been able to place stocks of safe blood at the disposal of the user, i.e. the hospital where the need arises. It is for this reason that central blood banks are now commonplace, serving vast urban population areas as in Sydney, and providing a wide range of blood components on demand. Scaled-down versions of the Sydney operation, still capable of producing components on demand, have been developed in more than half of our New South Wales Country Blood Banks.
Once collected into a container, the properties of the liquid blood begin to change. Viewed simply from chemical analysis, it is obvious that after collection blood loses progressively some of its normal biochemical as well as physical properties, irrespective of the manoeuvres aimed at minimising such changes. There are still some who believe that blood should be used immediately it is drawn from the donor "on the hoof", and that once stored it serves little useful purpose. In my view this is not the case. Modern blood bank practice stands on the production and issue of many blood components. The storage-dependent variables are now well recognised and blood components are matched to an individual patient's needs. The blood bank issues components in the knowledge that they will both survive adequately and perform the required physiological function after infusion. For instance, the accepted standard is 70070 (or better) survival of stored erythrocytes 24 hours after transfusion. Recognised levels of storagerelated change are acceptable in almost all circumstances where blood support is required, massive haemorrhage being an exception.
In this symposium the quality of stored blood products issued from a modern blood bank will be discussed from the viewpoint of support for a patient who is bleeding acutely. I shall not dwell on haemotherapy for other conditions.
PACKED CELLS AND WHOLE BLOOD
The blood bank inventory comprises whole blood and components of whole blood provided by blood donors and supplied on demand to the user (the medical profession) for the benefit of the patient. Until recently, Australian blood banks had little difficulty in meeting the 10-15070 annual increase in demand for blood. There are still no real problems in the provision of whole blood as such. However, the main target of blood banks now is maximum harvesting of the labile coagulation components which can only be processed from freshly drawn blood, and this demand will increase in the future. With the increase m component harvesting the cost of a unit of blood issued has escalated. In Australia blood donations are given voluntarily by unpaid donors, but the cost of a unit of blood issued (before cross-match) in Sydney is now well in excess of $40. To match the ever-increasing demand for components, particularly for fresh plasma, the blood bank might consider collecting even more whole blood with the intention of using the plasma and discarding the unused (unwanted) red blood cells. In my opinion this is unethical, expensive and wasteful.
The New South Wales Red Cross Blood Transfusion Service has adopted another approach 4 ,5 to blood storage with the acutely bleeding patient in mind, We have since 1977 maintained that the cornerstone of our inventory should be freely flowing red cell concentrates, obtained by a technical innovation that is now colloquially known as the "circle-pack" system. The modified red cell concentrates have been used increasingly for surgical conditions and other indications for which, in the past, only whole blood was considered suitable, At the same time the storage potential of liquid blood has improved, and currently the Service issues both the modified red cell concentrates and whole blood with a shelf-life of 35 days. With the extension of shelf-life, we have reduced outdating and wastage by at least 20070, while improving the flexibility of the inventory and decreasing turnover, The system has also proven useful in the practice of autologous blood transfusion. The prolongation of shelf-life should not be taken to mean that blood issued is just about to expire. At present 75070 of our blood stock is distributed to hospitals within two weeks of collection, and in terms of its physico-chemical properties this qualifies as fresh blood (Tables 1  and 2 ). As already mentioned, all blood and components comply with strict production standards and are subject to frequent appropriate quality assurance checks. Both storage and transport conditions must conform to the recommendations of the Blood Transfusion Service, which are in turn the subject of a continuing educational campaign at all levels of medical practice. It is also worth noting that blood, like any other biological variable, displays a range in storage-dependent physico-chemical changes which the Blood Transfusion Service has taken into account when setting criteria of acceptability for any of the blood products issued. One may therefore refute the (occasional) criticism that the accepted levels of change in stored blood are based only on information from laboratory protocols and are not applicable to conditions met in clinical practice. Table 3 lists information from routine checks performed over a two-year period by the Quality Control department of the Blood Transfusion Service in Sydney on a total of 270 modified red cell 7.2 (0.1) 6.8 (0.06) 6.6 (0.05) 168 (5) 160 (7) 156 (7) 30 (6) 40 (5) 48 (7) 75 (3) 55 (4) 49 (6) 66 (8) 10 (8) 10 (9) 0.05 0.2 (0.1) 0.3 (0.15) 86 (7) 78 (2) concentrates. If the desired therapeutic effect is to be attained, it is essential that those handling the blood after it leaves the Blood Transfusion Service should understand and comply with instructions concerning both storage and transport. For instance, one should remember that if blood has been left outside the refrigerator for more than one hour, it cannot be used. Tables 2 4 ,5 and 4 6 list some of the more important storage-dependent alterations in whole blood and in our modified concentrates respectively. Comparing the supernatants of red cell concentrates and whole blood, that of the concentrates appears to indicate the greater deterioration. This is not the case. Because whole blood gives about 2.5 times more supernatant, the total volume/load of metabolites is less in the modified concentrates. The exception is the relatively higher content of free haemoglobin, which is still within acceptable limits even for massive transfusions. It seems reasonable, then, to suppose that as much as three units of stored blood may safely be given to almost all adult patients, and this covers 85070 of all blood transfusions being given at the present time. When more blood is needed quickly and especially in the case of continuous acute haemorrhage, a judicious mix of blood less than two weeks old with blood of longer storage may be desirable.
The question of storage-dependent depletion of erythrocyte 2-3 biphosphoglycerate, which is one of the regulators of oxygen unloading to tissues, warrants particular mention. After three weeks' storage, insignificant amounts remain, but it is now known that this metabolite regenerates quickly following transfusion. Faced with the need for massive blood transfusion there is, in principle at least, an advantage in providing mainly fresh blood with normal oxygen unloading potential. However, the process of unloading oxygen to tissues is not dependent entirely on the concentration of 2-3 biphosphoglycerate. For instance, arterio-venous oxygen saturation differences, cardiac output, volume of organ blood perfusion, mean corpuscular haemoglobin concentration, temperature, and tissue pH, to name but a few, all interact in the regulation of oxygen delivery to tissues and sometimes independently of 2-3 biphosphoglycerate concentration. The significance of lower than normal levels of this metabolite and its relevance to clinical blood transfusion practice remains controversial, especially as it applies to blood replacement in massive acute haemorrhage. Discussing blood for treatment of massive haemorrhage, Collins 7 uses both historical data accumulated during the Vietnam war and the results of experiments on humans and animals to make the point that 2-3 biphosphoglycerate is in all probability secondary in importance to the maintenance of blood volume, prevention of hypotension and haematocrit value above 500/0 of normal. In any event it is important to note that at storage periods up to two weeks blood still has levels of 2-3 biphosphoglycerate to meet most clinical needs.
One could, then, conclude that in a patient with acute haemorrhage, provided blood volume is maintained, red cell loss could be met in the first instance by modified erythrocyte concentrates. 8 If it were necessary to follow with a massive transfusion, then whole blood or a mixture of red cell concentrate and whole blood might have to be given to avoid a fall in oncotic pressure. When more than 80% of the patient's blood volume has been replaced, one should also consider the possible benefit of platelet concentrates, plasma and/or concentrated haemostatic factors. On the other hand, when first dealing with a patient already suffering from massive blood loss and in whom bleeding has not been arrested, red cell concentrates may still be advantageous as a follow-up to whole blood after restoration of blood volume. It has been said that for such patients red cell concentrates may still be of advantage initially, because the total load of accumulated metabolites is significantly less than in whole blood. 9 Except in the most unusual event when dozens of units of blood must be given over a few hours, the shelf-age of blood appears to be a secondary consideration. The Blood Transfusion Service should always be able to supply fresh blood (i.e. blood stored for less than 14 days) and to supplement this when necessary with such other components as may be needed. The large central blood banks usually lack facilities for the immediate supply of blood from the "walking donor". In other than exceptional circumstances the demand for blood "on the hoof" leads to consternation among blood bankers, a situation "made doubly frustrating by the fact that the ordering physician often has as much difficulty defining the product as in justifying the request" .10 Despite the steady accumulation of storagedependent by-products in banked blood (Tables  2-4 ) it has been unusual to observe serious sideeffects, even in massive blood transfusion. Indeed, it is remarkable that only anecdotal reports appear in discussions of the potential untoward effects of accumulated wasteproducts in stored blood. The administration of stored blood in usual amounts (e.g. 3-4 donor units) in a non-compromised patient is not expected to cause serious side-effects. It is worth repeating that, compared with whole blood, for a given storage period, red cell concentrates have fewer unwanted metabolites, the plasma haemoglobin load being an exception. However, in a patient with significant pre-existing and particularly an active disease process, untoward effects may be expected after injection of very large volumes of stored blood alone. Prevention is better than cure and, depending on the underlying pathology, the patient's condition (haemorrhage apart) would guide one in using fresh (up to 14-day-old) blood rather than blood which is reaching the end of its shelf-life.
The dilutional "coagulopathy" already alluded to may appear with blood losses approaching patient's blood volume. Clearly red cell transfusions should be freely supplemented with platelet concentrates, fresh plasma and/or concentrated coagulation components for the correction of the underlying haemostatic deficiencies, if such are considered contributory to haemorrhage.
Another matter considered by some to be significant is the transfusion of micro aggregates which usually form in stored blood after ten days. In sensitised recipients their presence may lead to HLA-based febrile reactions. With massive transfusions of stored blood there is some indication from in vitro and animal experiment that large numbers of aggregates may compromise pulmonary circulation, leading to respiratory distress syndrome. The human clinico-pathological parallel is not clear, leading to the aphorism -"Microembolisation in blood transfusion: a non-disease for which we have a cure" .11 Nevertheless, a number of special terminal filtering devices have been produced, the users claiming benefits from the removal of microaggregates which will pass freely through the filter of the standard giving set. There are also many who have never used such devices and claim equally satisfactory results. In this service we have approached the matter along somewhat different lines. We have inserted a filtering device as an integral part of the circlepack system 12 to remove white cells and platelets soon after the blood has been collected from the donor. The full 35-day storage potential is not affected. The nidus for microaggregate formation is removed at the outset and the blood remains virtually microaggregate-free throughout storage. It should be remembered that both modified red cell concentrates and whole blood in their first week of storage, even without the use of a filter, contain but few microaggregates.
PLATELET CONCENTRATES
This blood component is now in routine production and issued on demand. Significant technical improvements have recently been introduced in "respiring" non-PVC (e.g. mellitate) based plastics which allow platelet viability for up to 7 days after collection. 13 The concentrates contain not less than 5.5 x 1010 platelets per pack, suspended in about 45 ml of plasma. Platelet concentrates must not be refrigerated. If blood is collected into the mellitate plastic, which allows for oxygen and carbon dioxide exchange and prevents pH fall below 6.5 and the platelet concentrate is agitated in a standard manner at 22 0 -24 DC, the Blood Transfusion Service allows 5-day dating.
It should be noted that infusion of a single unit of platelet concentrate is expected to raise the platelet level in the recipient by 10 x 10 9 per litre, provided there are no HLA or other immune anti-platelet antibodies present. We would expect that at least five units of donor blood "on the hoof" would be required to produce the same effect.
It is not possible completely to free the platelet concentrates of either white cells or erythrocytes, of which a small number remain as contaminants. This in practice precludes transfusion across the ABO barrier. It is left to the user to make the decision whether a number of platelet concentrates are to be pooled into a single container or transfused as discrete units.
FROZEN PLASMA
Whole plasma and cryosupernate plasma are issued as frozen components, the only practical difference being the prior extraction of cryopreci pi tate (con taining the an tihaemophilic factor and part of the fibrinogen) from the cryosupernate units. It would be fair to re-state the obvious, i.e. that even with the most massive transfusional requirement, depletion of factor VIII rarely contributes to bleeding tendency unless, of course, the patient has congenital deficiency or has acquired a specific anticoagulant. This is often forgotten and fresh frozen plasma is frequently used when cryosupernate would suffice.
It is accepted that frozen packs are brittle and that thawing frozen plasma is an inconvenience. Plasma should not be thawed in an ambient exceeding 37 DC. Recently the use of microwave ovens under strictly controlled conditions has been recommended,14,15 but it has not yet been proved that the effect of radiation is not harmful.
Plasma for transfusion should preferably be of the same ABO group as the patient. This becomes more important if plasma is given between transfusions of blood, or when the requirement is massive.
The composItIOn of frozen plasma is equivalent to that of whole blood at collection. Hypernatraemia and citrate overload may have to be considered in the case of a large transfusion. Frozen plasma should not be stored for more than six months from date of collection. CRYOPRECIPITATE A single donor unit of cryoprecipitate should contain von Willebrand's factor, approximately 80 units of antihaemophilic (factor VIII) coagulation activity and 230 mg of fibrinogen in about 15 ml of plasma. It is stored at -30 QC until required. There is no significant loss of activity for six months after production. Cryoprecipitate also contains fibronectin, considered by some as a useful adjunct to treatment of patients with significant traumatic wounds.
